Cargando…
The Emerging Role of PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer
Poly(ADP-ribose) polymerase-1 (PARP-1) is an important novel target in cancer therapy. This enzyme is essential in the repair of single-stranded breaks in DNA via the base excision repair pathway. Drugs which inhibit PARP are emerging as a promising new class of anticancer agents particularly effect...
Autores principales: | Gien, Lilian T., Mackay, Helen J. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2798102/ https://www.ncbi.nlm.nih.gov/pubmed/20049345 http://dx.doi.org/10.1155/2010/151750 |
Ejemplares similares
-
The role of PARP inhibitor combination therapy in ovarian
cancer
por: Hockings, Helen, et al.
Publicado: (2023) -
Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer
por: Revythis, Antonios, et al.
Publicado: (2022) -
New treatment option for ovarian cancer: PARP inhibitors
por: Meehan, Robert S., et al.
Publicado: (2016) -
PARP Inhibitors in Breast and Ovarian Cancer
por: Wang, Samuel S. Y., et al.
Publicado: (2023) -
PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective
por: Loizzi, Vera, et al.
Publicado: (2020)